Scorpion Therapeutics

Executive Summary

Scorpion Therapeutics is a precision oncology company leveraging an integrated platform combining chemical proteomics, structural biology, and computational tools to develop small molecule drugs against historically undruggable cancer targets. Founded in 2020 and based in Boston, the company has raised $150 million to advance its pipeline of novel therapies for genetically defined patient populations. Scorpion’s platform enables the identification of high-value targets and the design of best-in-class inhibitors, with a focus on overcoming resistance mechanisms and improving patient outcomes. The company is currently in Phase 1 clinical development, with lead programs targeting key oncogenic drivers. Recent progress includes the advancement of its lead candidate into dose-escalation studies and the expansion of its preclinical pipeline. Scorpion’s innovative approach and strong investor backing position it well to address significant unmet needs in oncology, though the early-stage nature of its programs entails inherent risk. The company remains private and is not publicly traded, limiting visibility but offering potential upside for future partnerships or funding events.

Upcoming Catalysts (preview)

• Q2 2025Phase 1 data readout for lead program ST-00160% success
• Q4 2025Investigational New Drug (IND) filing for next pipeline candidate70% success
• TBDPotential Series C financing or strategic partnership50% success